Every 10-Q that SCIENTIFIC INDUSTRIES INC (SCND) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SCND and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCND filings page.
Scientific Industries, Inc. reported higher revenue but continued losses for the quarter and six months ended June 30, 2026. Net revenues rose to $1,470,400 for the quarter and $2,697,500 for the six months, up from $1,081,000 and $2,023,300 in 2025, driven mainly by growth in Benchtop Laboratory Equipment and increased Bioprocessing Systems sales.
Gross margin improved to 42.3% for the quarter and 40.5% year-to-date, compared with 34.8% and 35.6% a year earlier, helped by higher-margin DOTS bioprocessing products. Operating expenses fell materially, with six‑month general and administrative costs down to $1,300,900 from $1,774,000 and selling expenses down to $1,334,200 from $1,528,100, reflecting headcount reductions and cost savings.
The company still recorded a six‑month loss from continuing operations of $(2,823,100), improved from $(3,854,900). Cash and cash equivalents were $616,500 and investment securities $3,932,000 at June 30, 2026. Net cash used in operating activities was $(1,897,600), better than $(3,204,500) in 2025. Management expects cash, investments, and proceeds and payments related to the 2025 Genie Division sale to fund operations for at least one year, while acknowledging reliance on expense reductions, revenue growth and potentially additional capital.
Scientific Industries, Inc. reports first-quarter 2026 results showing higher sales but continued losses as it invests in bioprocessing. Revenue rose to $1,227,100 from $942,300, driven by growth in both Benchtop Laboratory Equipment and Bioprocessing Systems, and gross margin improved to 38.3% from 36.5%.
The loss from continuing operations narrowed to $1,589,300 from $2,057,100, with basic and diluted loss per share improving to $(0.13) from $(0.16), helped by lower general and administrative and selling expenses. Research and development spending increased as new bioprocessing products were developed.
Cash and cash equivalents were $797,800 and investment securities were $4,853,000 as of March 31, 2026. Operating activities used $993,500 of cash in the quarter. Management cites proceeds and follow-on agreements from the 2025 Genie Division sale as support for funding operations for at least one year, while acknowledging an accumulated deficit of $36,740,200 and expected ongoing negative operating cash flows.
Scientific Industries, Inc. (SCND) reported a sharp turnaround in Q3 2025 driven by the sale of its Genie Division. Net revenues from continuing operations for the quarter rose to $1,404,000 from $1,334,400, mainly from higher Torbal VIVID pill counter sales, while Bioprocessing revenues declined. Despite this, continuing operations still generated a quarterly operating loss of $1,522,300.
The August 7, 2025 sale of the Genie Division to Troemner, LLC produced a gain of $5,263,400 on consideration of $9,600,000 (before adjustments), resulting in Q3 net income of $3,994,400 versus a net loss of $1,180,100 a year earlier. For the nine months, the company posted net income of $692,200 compared with a $4,515,400 loss in 2024, even as it recorded a $5,434,700 loss from continuing operations and used $4,390,700 of cash in operating activities. Cash and cash equivalents were $1,162,600 and investment securities $7,131,100 as of September 30, 2025, and shareholders’ equity increased to $12,461,700.